Matches in Wikidata for { <http://www.wikidata.org/entity/Q93021744> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- Q93021744 description "article scientifique publié en 2019" @default.
- Q93021744 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q93021744 description "scientific article published on 01 October 2019" @default.
- Q93021744 description "wetenschappelijk artikel" @default.
- Q93021744 description "наукова стаття, опублікована 1 жовтня 2019" @default.
- Q93021744 name "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 name "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 type Item @default.
- Q93021744 label "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 label "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 prefLabel "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 prefLabel "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 P1433 Q93021744-1CC0CEAB-28E8-434A-9646-CB4122E9BBC1 @default.
- Q93021744 P1476 Q93021744-E7C5436D-23F9-4414-8406-B37937546EB9 @default.
- Q93021744 P2093 Q93021744-13BBBA60-1E4B-4CE9-BA20-3F15423A1DA4 @default.
- Q93021744 P2093 Q93021744-19C81C05-D5BB-4674-B730-88DB444869F3 @default.
- Q93021744 P2093 Q93021744-2B03D7E5-3EA3-4078-92FA-C848D093B591 @default.
- Q93021744 P2093 Q93021744-425EC333-201B-4489-ABFB-6F002771EF65 @default.
- Q93021744 P2093 Q93021744-532837AF-3224-4C0A-A37F-BD278F58B481 @default.
- Q93021744 P2093 Q93021744-5AF55018-319B-479F-976A-7738F5C82B85 @default.
- Q93021744 P2093 Q93021744-64E2F3D4-E84A-4B58-A3A0-8D1E16958829 @default.
- Q93021744 P2093 Q93021744-6D2A21F7-876C-43A2-913E-28022678035B @default.
- Q93021744 P2093 Q93021744-7923F8E0-FB43-41D9-A129-0AC127348B9B @default.
- Q93021744 P2093 Q93021744-870E8685-FE7E-4FAA-A821-0F5604FFE03A @default.
- Q93021744 P2093 Q93021744-8FAF9C9F-AC14-4442-8E90-79F4E3ABBC34 @default.
- Q93021744 P2093 Q93021744-90A76FED-8949-4C86-A4A2-2B4CD8488DD4 @default.
- Q93021744 P2093 Q93021744-97E741FE-28D8-4CC9-906E-1EB470E835FF @default.
- Q93021744 P2093 Q93021744-A893900B-686A-48CF-98C5-C0DD2A678317 @default.
- Q93021744 P2093 Q93021744-B2898AFE-C482-4D39-BA12-6A6CB42BAD90 @default.
- Q93021744 P2093 Q93021744-E1B7311D-0680-447C-999A-4FF16FAD0B51 @default.
- Q93021744 P2093 Q93021744-E8F3D4D7-66C9-4544-8C88-E3DB2329FF50 @default.
- Q93021744 P2093 Q93021744-ED699AA9-423B-4DD9-93BD-E2EB45BAA6C0 @default.
- Q93021744 P2093 Q93021744-F7FAF51C-3AB2-4F6C-B563-6BA6219D1602 @default.
- Q93021744 P2093 Q93021744-FAB0A62F-B725-4C08-96FD-D7A50C758FA5 @default.
- Q93021744 P2093 Q93021744-FE9266CC-8CCA-4035-8B8B-FDE62379271A @default.
- Q93021744 P304 Q93021744-17D168CD-D59B-4082-8A41-83DB0BE843B3 @default.
- Q93021744 P31 Q93021744-FC80487A-CCAF-4F46-910C-3065717DD34F @default.
- Q93021744 P356 Q93021744-297F6D95-A99B-4467-9083-C710FE1CB3F8 @default.
- Q93021744 P433 Q93021744-A3990CBF-E834-43C4-A2C0-5B5F3CC4887C @default.
- Q93021744 P478 Q93021744-9701F684-DB3E-4366-B12A-17635C5CA448 @default.
- Q93021744 P50 Q93021744-33971224-4E20-445B-AAD9-68B038E82E9C @default.
- Q93021744 P50 Q93021744-A07E78B9-F417-4A32-BAA6-88BEB956CD6F @default.
- Q93021744 P50 Q93021744-B594D972-CAC6-4A19-BFB5-AE4E9A4ED0AE @default.
- Q93021744 P50 Q93021744-D3DF5B19-15A7-4B67-B460-DB3A05E53F86 @default.
- Q93021744 P577 Q93021744-65D83903-E5C4-4A5E-ADBA-2B072A3C849B @default.
- Q93021744 P698 Q93021744-A02291AC-D6E4-4C4E-BFB9-155EC6604859 @default.
- Q93021744 P356 BLOOD.2019001285 @default.
- Q93021744 P698 31471376 @default.
- Q93021744 P1433 Q885070 @default.
- Q93021744 P1476 "Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study" @default.
- Q93021744 P2093 "Ahmed Sawas" @default.
- Q93021744 P2093 "Aishling M Rada" @default.
- Q93021744 P2093 "Alberto Risueño" @default.
- Q93021744 P2093 "Alice T Jacob" @default.
- Q93021744 P2093 "Andrei R Shustov" @default.
- Q93021744 P2093 "Bin Cheng" @default.
- Q93021744 P2093 "Changchun Deng" @default.
- Q93021744 P2093 "Craig R Soderquist" @default.
- Q93021744 P2093 "Cristina Kinahan" @default.
- Q93021744 P2093 "Daniel Menezes" @default.
- Q93021744 P2093 "David C Park" @default.
- Q93021744 P2093 "Francesca Montanari" @default.
- Q93021744 P2093 "Hye A Kim" @default.
- Q93021744 P2093 "Jennifer E Amengual" @default.
- Q93021744 P2093 "Jennifer K Lue" @default.
- Q93021744 P2093 "Karen Khan" @default.
- Q93021744 P2093 "Lubomir Sokol" @default.
- Q93021744 P2093 "Luigi Scotto" @default.
- Q93021744 P2093 "Mark M Francescone" @default.
- Q93021744 P2093 "Michelle Malanga" @default.
- Q93021744 P2093 "Renu Nandakumar" @default.
- Q93021744 P304 "1395-1405" @default.
- Q93021744 P31 Q13442814 @default.
- Q93021744 P356 "10.1182/BLOOD.2019001285" @default.
- Q93021744 P433 "17" @default.
- Q93021744 P478 "134" @default.
- Q93021744 P50 Q104437536 @default.
- Q93021744 P50 Q38546986 @default.
- Q93021744 P50 Q41564849 @default.
- Q93021744 P50 Q91794992 @default.
- Q93021744 P577 "2019-10-01T00:00:00Z" @default.
- Q93021744 P698 "31471376" @default.